Pliant Therapeutics (PLRX) Total Non-Current Liabilities (2019 - 2021)
Pliant Therapeutics (PLRX) posted quarterly Total Non-Current Liabilities of $22.2 million for Q4 2021, up 91.02% year-over-year from $11.6 million in Q4 2020, and up 71.42% quarter-over-quarter from $12.9 million in Q3 2021.
Pliant Therapeutics (PLRX) Total Non-Current Liabilities (2019 - 2021) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Total Non-Current Liabilities for 3 consecutive years, with $22.2 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Total Non-Current Liabilities rose 91.02% year-over-year to $22.2 million; the TTM figure through Dec 2021 stood at $22.2 million (up 91.02% YoY), while the FY2021 annual figure was $22.2 million, up 91.02% from the prior year.
- Total Non-Current Liabilities climbed to $22.2 million in Q4 2021 per PLRX's latest filing, from $12.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $22.2 million in Q4 2021 and bottomed at $8.2 million in Q4 2019.
- Historically, Total Non-Current Liabilities has averaged $12.4 million across 3 years, with a median of $11.3 million in 2020.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 91.02% in 2021 and fell as far as 9.17% in 2021.
- Pliant Therapeutics' Total Non-Current Liabilities stood at $8.2 million in 2019, then soared by 41.94% to $11.6 million in 2020, then surged by 91.02% to $22.2 million in 2021.
- Business Quant data shows PLRX's Total Non-Current Liabilities at $22.2 million in Q4 2021, $12.9 million in Q3 2021, and $10.9 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 9.32 Bn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 22.16 Mn |
| Sep 30, 2021 | 12.93 Mn |
| Jun 30, 2021 | 10.93 Mn |
| Mar 31, 2021 | 10.25 Mn |
| Dec 31, 2020 | 11.60 Mn |
| Sep 30, 2020 | 11.03 Mn |
| Jun 30, 2020 | 12.04 Mn |
| Dec 31, 2019 | 8.17 Mn |